These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38649782)

  • 41. Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study.
    Alharbi A; Yousef A; Zubani A; Alzahrani M; Al-Hindi M; Alharbi S; Alahmadi T; Alabdulkarim H; Kazmierska P; Beuvelet M
    Adv Ther; 2024 Apr; 41(4):1419-1435. PubMed ID: 38356106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
    Coma E; Martinez-Marcos M; Hermosilla E; Mendioroz J; Reñé A; Fina F; Perramon-Malavez A; Prats C; Cereza G; Ciruela P; Pineda V; Antón A; Ricós-Furió G; Soriano-Arandes A; Cabezas C
    Arch Dis Child; 2024 Aug; 109(9):736-741. PubMed ID: 38857952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.
    Zornoza Moreno M; Pérez Martín JJ; Moreno MCG; Abellán MPR
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357439. PubMed ID: 38857859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia.
    Buendía JA; Acuña-Cordero R; Rodriguez-Martinez CE
    Pediatr Pulmonol; 2024 May; 59(5):1372-1379. PubMed ID: 38358037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
    Domachowske JB; Chang Y; Atanasova V; Cabañas F; Furuno K; Nguyen KA; Banu I; Kubiak RJ; Leach A; Mankad VS; Shroff M; Takas T; Villafana T; Wählby Hamrén U
    J Pediatric Infect Dis Soc; 2023 Aug; 12(8):477-480. PubMed ID: 37466917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.
    Eick A; Karron R; Shaw J; Thumar B; Reid R; Santosham M; O'Brien KL
    Pediatr Infect Dis J; 2008 Mar; 27(3):207-12. PubMed ID: 18277934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities.
    Ananworanich J; Heaton PM
    Vaccines (Basel); 2021 Aug; 9(9):. PubMed ID: 34579198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nirsevimab: A Review.
    Balbi H
    Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.
    Gimenez HB; Chisholm S; Dornan J; Cash P
    Clin Diagn Lab Immunol; 1996 May; 3(3):280-6. PubMed ID: 8705669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection.
    Schmidt ME; Meyerholz DK; Varga SM
    Mucosal Immunol; 2020 May; 13(3):507-517. PubMed ID: 31844172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants.
    Principi N; Autore G; Perrone S; Esposito S
    Expert Opin Pharmacother; 2023 Apr; 24(6):747-762. PubMed ID: 37013721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants.
    Patel SM; Jallow S; Boiditswe S; Madhi SA; Feemster KA; Steenhoff AP; Arscott-Mills T; Muthoga C; Ajibola G; Shapiro R; Shah SS; Cunningham CK; Kelly MS
    J Pediatric Infect Dis Soc; 2020 Jul; 9(3):349-356. PubMed ID: 31549157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Game over for RSV?
    Strine MS; Wilen CB
    Sci Immunol; 2023 Jun; 8(84):eadi8764. PubMed ID: 37276355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice.
    Lee Y; Klenow L; Coyle EM; Grubbs G; Golding H; Khurana S
    Nat Commun; 2024 Apr; 15(1):2900. PubMed ID: 38575575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.